Literature DB >> 4753871

Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.

W J Weiner, H L Klawans.   

Abstract

Lumbar cerebrospinal fluid homovanillic acid levels were estimated in 60 patients with Parkinsonism before and during levodopa treatment. There was a slight negative correlation between pretreatment CSF homovanillic acid levels and disability. There was no correlation between pretreatment homovanillic acid levels and clinical response to levodopa. Patients with high pretreatment levels did as well as those with depressed levels. High (normal or near normal) levels of CSF homovanillic acid in a patient with Parkinsonism do not necessarily indicate that the Parkinsonism will not respond to levodopa. These patients should receive the benefit of a trial of levodopa. There was also no correlation between homovanillic acid level during tratment and improvement. Patients with minimal increases in CSF homovanillic acid responded as well as those with greater elevations. Failure of levodopa to increase CSF homovanillic acid significantly does not indicate that the patient will not respond to levodopa and that levodopa should be discontinued. Other factors, such as vitamin B(6) consumption, should be investigated.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4753871      PMCID: PMC494452          DOI: 10.1136/jnnp.36.5.747

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  17 in total

1.  On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method.

Authors:  N E ANDEN; B E ROOS; B WERDINIUS
Journal:  Life Sci (1962)       Date:  1963-07

2.  A method for evaluating disability in patients with Parkinson's disease.

Authors:  G J CANTER; R DE LA TORRE; M MIER
Journal:  J Nerv Ment Dis       Date:  1961-08       Impact factor: 2.254

3.  Catecholamine metabolism during oral administration of levodopa.

Authors:  H Hinterberger; C J Andrews
Journal:  Arch Neurol       Date:  1972-03

4.  Treatment of parkinsonism with L-dopa (study of 105 patients).

Authors:  H L Klawans; J S Garvin
Journal:  Dis Nerv Syst       Date:  1969-11

5.  Concentrations of 5-hydroxyindolylacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid.

Authors:  H C Guldberg; G W Ashcroft; T B Crawford
Journal:  Life Sci       Date:  1966-09       Impact factor: 5.037

6.  On the origin of homovanillic acid in the cerebrospinal fluid.

Authors:  G Bartholini; A Pletscher; R Tissot
Journal:  Experientia       Date:  1966-09-15

7.  Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease.

Authors:  U K Rinne; V Sonninen
Journal:  Neurology       Date:  1972-01       Impact factor: 9.910

Review 8.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

9.  A fluorimetric method for the estimation of 4-hydroxy-3-methoxyphenylacetic acid (homovanillic acid) and its identification in brain tissue.

Authors:  D F SHARMAN
Journal:  Br J Pharmacol Chemother       Date:  1963-02

10.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15
View more
  5 in total

1.  Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.

Authors:  G Campanella; S Algeri; C Cerletti; E Dolfini; A Jori; F Rinaldi
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

4.  CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.

Authors:  D L Davidson; C M Yates; C Mawdsley; I A Pullar; H Wilson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-12       Impact factor: 10.154

Review 5.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.